Comprehensive Molecular Tumour Analysis (CMTA) Integrating RNAseq and TME for Targeted Therapy
The Evolving Landscape of Precision Oncology: CMTA and RNA Sequencing
Dr. Marie-Laure Yaspo discusses The landscape of cancer diagnosis and treatment is rapidly evolving, with precision oncology standing as a beacon of hope. This field’s progress is largely driven by the integration of RNA sequencing (RNA-seq) and tumour microenvironment (TME) analysis through Comprehensive Molecular Tumour Analysis (CMTA). This blog will explore the significance of CMTA and the critical role of MGI sequencers.
Understanding Comprehensive Molecular Tumour Analysis (CMTA)
CMTA marks a paradigm shift in cancer diagnostics, offering a holistic view of a patient’s tumour biology. It integrates exome sequencing with transcriptome analysis, maximizing the chances of identifying actionable targets for personalized therapies.
Key Advantages of CMTA
Maximizing Treatment Options
Uncovers a wide range of mutations and alterations to guide targeted therapy selection beyond standard protocols.
Inclusion of Rare Cancers
Offers new possibilities and diagnostic pathways for rare cancers and pediatric cases.
Advanced Disease Insights
Unearths complex genetic abnormalities in metastatic and refractory cancers during advanced stages.
Clinical Trial Matching
Precisely assists in matching patients with relevant clinical trials based on their unique molecular profile.
MGI Sequencers Supporting CMTA
MGI sequencing platforms provide the flexibility, speed and precision required for comprehensive molecular tumour analysis workflows.
DNBSEQ-G400
Reliable and versatile sequencing for routine clinical and research workflows.
DNBSEQ-G99
Fast turnaround and efficiency for time-sensitive laboratory environments.
DNBSEQ-T7
High-throughput scalability with precise data generation for demanding applications.
Enhancing CMTA Workflows
Integrated sequencing solutions improve accuracy and efficiency in molecular analysis.
Comprehensive Profiling
Supports broader studies and detection of rare genomic alterations.
Flexible Workflows
Adapts to varied oncology and tumour microenvironment studies.
Faster Results
Reduces turnaround time for clinically relevant reporting.
Unlocking the Full Potential of CMTA
Combining exome and transcriptome data provides a deeper understanding of tumour biology and supports personalised oncology.
Complete Tumour Profiling
Multiomic analysis delivers a broader biological perspective for better decisions.
Rare Cancer Research
Helps uncover genomic complexity in underrepresented cancer types.
As we stand on the threshold of a new era, precision medicine promises to reshape our approach to cancer. Powered by MGI sequencers, the integration of exome sequencing and transcriptome analysis holds the potential to provide every patient with tailored treatment options. This synergy represents a beacon of hope and a massive leap forward in the fight against cancer.
Disclaimer: The information provided in this blog is for educational and informational purposes only and is not intended for use in diagnostic procedures. MGI products mentioned are for research use only.
Published 7 December 2022
